AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00885495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin, darunavir, ritonavir
Description: rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
Study NCT02838004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL MINI WELL READY
Description: IOL MINI WELL READY
Study NCT03513198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound (including fine needle aspiration)
Description: EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.~* Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.~* Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~* EUS-FNA will be performed in all pancreatic masses with at least four passes.
Study NCT03513198 — intervention group
Intervention type: OTHER
Intervention: Contrast-enhanced endoscopic ultrasound (CE-EUS)
Description: CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.~* The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).~* The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.~* All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box
Study NCT03513198 — intervention group
Intervention type: OTHER
Intervention: Endoscopic ultrasound elastography (EG-EUS)
Description: EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD~* The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided~* The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.~* SR and SH will be measured; with three measurements made and recorded on the embedded HDD.
Study NCT03513198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced computed tomography (CT)
Description: * Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.~* A template will be used to report the imaging results.~* The template includes morphologic, arterial, venous, and extrapancreatic evaluations.~* Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).
Study NCT02475044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: 16 Sessions of CBT.
Study NCT03862443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Incentive
Description: The Fixed Incentive intervention is a fixed reward, in which participants are eligible for fixed weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
Study NCT03862443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drawing Incentive
Description: The Drawing Incentive intervention is a drawing reward, in which participants are eligible for weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
Study NCT03577145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato, onion & lovage soup with inulin
Description: Source of polyphenols and non digestible carbohydrate
Study NCT03577145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato, onion & lovage soup
Description: Source of polyphenols
Study NCT03577145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Source of non digestible carbohydrate
Study NCT03318601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood taking
Description: Blood taking in 2 times :~* J0 : 15 mL~* J14 : 5 mL 20 mL in total volume
Study NCT02328599 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery involving Roux-en-Y gastric bypass
Description: Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
Study NCT02328599 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery involving Laparoscopic adjustable gastric banding
Description: Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
Study NCT02328599 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery involving Laparoscopic sleeve gastrectomy
Description: Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
Study NCT02167204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-FLT PET/CT
Study NCT02167204 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo 18F-FLT PET/CT
Study NCT00274794 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Description: 10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
Study NCT00274794 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: 375 mg/m2, IV, Once per week for 3 weeks.
Study NCT02167204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FLT PET/CT
Study NCT03074305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI for in-bioresorbable scaffold stenosis
Description: In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~1. DEB strategy~2. DES strategy
Study NCT02844504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercise Training 1
Description: Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
Study NCT02844504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercise Training 2
Description: Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
Study NCT01125644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPK-843
Description: SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
Study NCT03387579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoflipid 20% Lipid Emulsion for Injection
Description: Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
Study NCT01009775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: intravenous infusion
Study NCT01009775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion
Study NCT03387579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
Study NCT03387579 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
Study NCT04514276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consecutive fetoneonatal healthcare pathway
Description: (1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
Study NCT01691443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure sensor and wrist shaker, not marked CE, developped by Texisense
Study NCT00185367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Description: 7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
Study NCT00185367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH D 593 B (Miranova)
Description: 7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
Study NCT03358212 — intervention group
Intervention type: DRUG
Intervention: Denosumab
Description: Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment
Study NCT02507219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
Study NCT02507219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
Study NCT04581239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active neural mobilization
Description: Active neural mobilization Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization.~Active oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set
Study NCT04581239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive neural mobilization
Description: Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization~Passive neural mobilization This oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set. Both groups received total 18 session 3 session per week for consecutive 6 weeks
Study NCT04234568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04234568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04234568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV
Study NCT04234568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04234568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given PO
Study NCT01120028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
Study NCT01120028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
Study NCT01120028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
Study NCT01120028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
Study NCT03947658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical crown lengthening
Description: Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation
Study NCT02699866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLT Implant Ø 2.9 mm
Description: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
Study NCT03701451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demethylated drug decitabine
Description: Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
Study NCT01491464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/INTER FIX™
Description: The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
Study NCT01491464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/INTER FIX™
Description: The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
Study NCT03095781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL888
Description: Given PO
Study NCT03095781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02579577 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
Study NCT02579577 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
Study NCT02579577 — intervention group
Intervention type: OTHER
Intervention: Medical notes review
Description: The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
Study NCT04257461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluoropyrimidine
Description: Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
Study NCT04636580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent accompanying the child during treatment
Description: After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
Study NCT03794544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Study NCT03794544 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Study NCT03794544 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Study NCT03794544 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Study NCT01386645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low glycemic index (LGI) diet
Description: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab
Study NCT01386645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high glycemic index (HGI) diet plus placebo (PLAC)
Description: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
Study NCT00442286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rheos® Baroreflex Hypertension System
Description: Electrical activation of the Carotid Baroreflex
Study NCT04997967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine/Propofol
Description: The level of sedation was assessed at 1-3 min intervals, and the infusion rate was adjusted accordingly to achieve a Ramsay Sedation Scale (RSS) score of 5. Any movement of the patient was treated by increasing infusion rate and the infusion was discontinued at the end of the procedure. The total propofol consumed was calculated and the recovery time was recorded and calculated as the time from discontinuation of infusion of the study drug till achievement of RSS score of 3. Then patients were discharged to post-anesthesia care unit (PACU) after attaining an Aldrete Recovery Scale Score of 9- 10 \[19\]. Time taken to achieve this score was also recorded.
Study NCT04997967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
Study NCT02659644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral L-citrulline
Description: There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
Study NCT03564054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Participants on this arm will be treated with photodynamic therapy. PDT is a two-stage process. The first stage of PDT is the intravenous injection of porfimer sodium (Photofrin) administered as a single slow intravenous injection over 3 to 5 minutes. The second stage involves the application of laser light to the tumor by bronchoscopy.
Study NCT03564054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation
Description: Participants on this arm will be treated with argon plasma coagulation. A flexible probe housing a wire delivers high-frequency, high-voltage electric current to a monopolar tungsten electrode present at the tip of the probe. Argon gas flows through the probe, and is charged or ionized to produce plasma as it flows around the tungsten electrode. Electric current flows through the plasma to the nearest tissue, and heat is produced as it passes through the tissue. Increased resistance created by coagulated tissue impairs the flow of electric current, and keeps the ablation depth to 1 to 2 mm.
Study NCT00075803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients > 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients \< 12 years, intravenous doses will be prepared.